Magdalena Pluta

Magdalena Pluta

Auto-generated profile, based on publicly available information

Magdalena Pluta

Department of Children's Infectious Diseases, Warszawski Uniwersytet Medyczny, Warszawa, Poland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Maria Pokorska-ŚpiewakMaria Pokorska-Śpiewak
Maria Pokorska-Śpiewak
BKBarbara Kowalik-Mikołajewska
Barbara Kowalik-Mikołajewska
MAMałgorzata Aniszewska
Małgorzata Aniszewska
MPMagdalena Pluta
Magdalena Pluta
Magdalena M MarczyńskaMagdalena M Marczyńska
Magdalena M Marczyńska
Liver biopsy is a standard method used for obtaining liver tissue for histopathological evaluation. Since reliable serological and virological tests are currently available, liver biopsy is no longer needed for the etiological diagnosis of chronic hepatitis B and C. However, liver histology remains the gold standard as a prognostic tool, providing information about the liver disease progression (grading of necroinflammatory activity and staging of fibrosis) and serving clinicians in the management and therapeutic decisions. In general, histopathological evaluation is indicated before starting the antiviral treatment. Main limitations of the liver biopsy include its invasive and painful procedure, sampling errors and the inter- and intra-observer variability. In addition, indications for the liver biopsy in pediatric patients with chronic viral hepatitis were questioned recently, and efforts have been made toward the development of non-invasive methods as an alternative to the liver biopsy. The most commonly used methods are novel imaging studies (elastography) and combinations of biomarkers. However, to date, none of these tests was validated in children with chronic viral hepatitis. In this review, we present the current status of the liver biopsy in the management of chronic viral hepatitis B and C in pediatric population, including specific indications, complications, contraindications, problems, limitations, and alternative non-invasive methods.

23 May 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Maria Pokorska-ŚpiewakMaria Pokorska-Śpiewak
Maria Pokorska-Śpiewak
BKBarbara Kowalik-Mikołajewska
Barbara Kowalik-Mikołajewska
MAMałgorzata Aniszewska
Małgorzata Aniszewska
MPMagdalena Pluta
Magdalena Pluta
Magdalena M MarczyńskaMagdalena M Marczyńska
Magdalena M Marczyńska
There is a need for validation of noninvasive alternatives to liver biopsy for the evaluation of fibrosis in children with chronic hepatitis C (CHC). The aim of this study was to evaluate the diagnostic performance of serum biomarkers modified by the body mass index z-score (BMI z-score) for the detection of fibrosis and steatosis in children with CHC. Thirty children aged 9.4 ± 3.7 years (14 males, 16 females) with CHC underwent liver biopsy. Fibrosis was scored using a 5-point METAVIR scale (≥2 = significant fibrosis). For all the children, the following noninvasive markers were calculated: The aspartate transaminase (AST)-to-platelets ratio index (APRI), the modified APRI (M-APRI: BMI z-score × APRI), the Fibrosis-4 index (FIB-4), the modified FIB-4 (M-FIB-4: BMI z-score × FIB-4), and a novel marker, B-AST (BMI z-score × AST). The area under the receiver operator characteristic curve (AUROC) was calculated to detect significant fibrosis and steatosis. In the histopathological evaluation, 22/30 (73%) patients presented with fibrosis, and 8/30 (27%) presented with steatosis. For the detection of significant fibrosis, the AUROCs for M-APRI, M-FIB-4 and B-AST were 0.842, 0.823, and 0.848, respectively. For significant steatosis, the AUROCs were more than 0.9 for all markers that included the BMI z-score. B-AST, with a cut-off of 92.8, showed 71% sensitivity and 95% specificity for detecting significant fibrosis. For predicting severe steatosis, B-AST had 100% sensitivity and 92% specificity. Negative values of all three markers that included BMI z-scores excluded all patients with both significant fibrosis and significant steatosis. Including the BMI z-score in serum biomarker formulas enhances their diagnostic ability to detect significant fibrosis and steatosis. B-AST may thus act as an effective alternative to liver biopsy.

1 January 2017 in Medicine
Verified
Journal Article
Open access
Maria Pokorska-ŚpiewakMaria Pokorska-Śpiewak
Maria Pokorska-Śpiewak
BKBarbara Kowalik-Mikołajewska
Barbara Kowalik-Mikołajewska
MAMałgorzata Aniszewska
Małgorzata Aniszewska
MPMagdalena Pluta
Magdalena Pluta
BWBożena Walewska-Zielecka
Bożena Walewska-Zielecka
Magdalena M MarczyńskaMagdalena M Marczyńska
Magdalena M Marczyńska
Only scarce data on liver steatosis in children with chronic hepatitis B and C (CHB and CHC) are available. The objective of this study was to evaluate the prevalence, predictors, and impact of hepatic steatosis on children with CHB and CHC. A total of 78 patients aged 11.5 ± 3.4 years were included: 30 (38%) had CHB, and 48 (62%) had CHC. Steatosis was scored on a 5-point scale, as follows: absent; minimal (≤5% hepatocytes affected), mild (6-33%), moderate (34-66%), and severe (>66%). Stepwise logistic regression was used to determine the factors associated with steatosis and moderate-to-severe steatosis. Steatosis was observed in 4/30 (13%) patients with CHB and 13/48 (27%) patients with CHC (P = 0.17). Moderate-to-severe steatosis was observed in 6/78 (8%) patients: 1/30 (3%) had CHB and 5/48 (10%) had CHC (P = 0.40). The body mass index (BMI) z-score was positively associated with the presence of steatosis in children with CHB (odds ratio [OR] = 3.3, 95% confidence interval [CI]: 1.02-10.64). In CHC, steatosis occurred more frequently in patients with hepatitis C virus genotype 3 compared with other genotypes (P = 0.002). In patients with non-3 genotype hepatitis C virus, steatosis was associated with the stage of fibrosis (OR = 3.35, 95% CI: 1.01-11.07) and inversely associated with the duration of infection (OR = 0.74, 95% CI: 0.55-0.97). Moderate-to-severe steatosis was positively associated with the BMI z-score (OR = 3.62, 95% CI: 1.22-10.75) and stage of fibrosis (OR = 3.89, 95% CI: 1.05-14.47). Steatosis is a common finding in children with chronic viral hepatitis. It is associated with metabolic factors in CHB, whereas in patients with CHC, metabolic and viral factors may have a combined effect, leading to more advanced grades of steatosis in children with higher BMI z-scores. Moderate-to-severe steatosis is a predictor of advanced fibrosis in children with CHC.

1 January 2015 in Polish Journal of Pathology
Verified
Journal Article
Open access
Maria Pokorska-ŚpiewakMaria Pokorska-Śpiewak
Maria Pokorska-Śpiewak
BKBarbara Kowalik-Mikołajewska
Barbara Kowalik-Mikołajewska
MAMałgorzata Aniszewska
Małgorzata Aniszewska
MPMagdalena Pluta
Magdalena Pluta
BWBożena Walewska-Zielecka
Bożena Walewska-Zielecka
Magdalena M MarczyńskaMagdalena M Marczyńska
Magdalena M Marczyńska
Histopathological features and determinants of liver disease progression were analyzed in 42 treatment-naïve children (mean age: 10.7 ±3.7) with chronic hepatitis C (14/42 infected vertically and 26/42 horizontally). Histopathological evaluation was performed according to Knodell’s modified system. Predictors of necroinflammation and fibrosis were identified using linear regression analyses. Most children presented with mild necroinflammation and fibrosis (mean grade 4.3 ±2.7, mean staging 1.2 ±0.8), irrespective of the mode of transmission. Vertically infected children were younger than those infected horizontally (8.6 ±2.5 vs. 11.5 ±3.7 years, p = 0.02). Alanine and aspartate aminotransferase (ALT and AST) levels were associated with necroinflammation (p = 0.003 and p = 0.01 for ALT and AST, respectively) and fibrosis (p = 0.01 and p = 0.04, respectively). Other positive independent predictors of fibrosis included duration of infection (p = 0.03) and body mass index (BMI) z-score (p = 0.03). Children with chronic hepatitis C presented with mild liver changes over a decade after the infection, irrespective of the mode of transmission. Since fibrosis is a time-dependent process, progression of the liver disease in vertically infected children may occur at a younger age compared to patients infected horizontally. Aminotransferase levels were associated with necroinflammation and fibrosis. Longer duration of infection and a higher BMI z-score were associated with more severe fibrosis.

1 January 2017 in Clinical and Experimental Hepatology
Verified
Journal Article
Open access
PDF file
Maria Pokorska-ŚpiewakMaria Pokorska-Śpiewak
Maria Pokorska-Śpiewak
BKBarbara Kowalik-Mikołajewska
Barbara Kowalik-Mikołajewska
MAMałgorzata Aniszewska
Małgorzata Aniszewska
MPMagdalena Pluta
Magdalena Pluta
Magdalena M MarczyńskaMagdalena M Marczyńska
Magdalena M Marczyńska
Aim of the study was to evaluate liver disease severity in children with chronic viral hepatitis using the FibroTest and ActiTest (FT/AT), and compare the results with the liver biopsy. Material and methods: The study included 11 treatment-naïve children [mean age, 9.0 ± 3.0 years, 10...

18 December 2020 in Klinische Padiatrie
Verified
Journal Article
Closed access
PDF file
MPMagdalena Pluta
Magdalena Pluta
MPMaria Pokorska-Śpiewak
Maria Pokorska-Śpiewak
MAMałgorzata Aniszewska
Małgorzata Aniszewska
BKBarbara Kowalik-Mikołajewska
Barbara Kowalik-Mikołajewska
MMMagdalena Marczyńska
Magdalena Marczyńska
Chronic hepatitis C (CHC) is a global health burden. Mother-to-child transmission (MTCT) accounts for most HCV infections in pediatric patients. Spontaneous viral clearance may occur in early childhood but is uncommon thereafter. Infection is usually asymptomatic during childhood, although without an effective treatment, vertically infected children may develop serious liver complications including cirrhosis and hepatocellular carcinoma in adulthood. Despite the lack of vaccine against hepatitis C and effective post-exposure methods of prevention of MTCT, treatment with direct-acting antiviral agents (DAAs) raised the prospect of eliminating HCV on a population level. Highly effective, well-tolerated, oral, and interferon-free regimens of short duration have revolutionized treatment of CHC. However, access to these therapies might be limited because of its high cost. In this review, we provide the current state of knowledge on the epidemiology, testing, monitoring and treating of HCV in children. We outline the remaining gaps in therapy and barriers to disease eradication.